Natural Alternatives International, Inc.

What they do

NAI manufactures vitamins, minerals, herbal and other nutritional supplements on a private-label contract basis for customers in the U.S. and abroad. It also sells and licenses raw material ingredients, primarily beta-alanine under the CarnoSyn, SR CarnoSyn, and TriBsyn trademarks, deriving revenue from direct sales, royalties, and supply agreements. Operations include manufacturing facilities in Vista and Carlsbad, California, and a wholly-owned subsidiary facility in Manno, Switzerland.

Revenue drivers

• Private-label contract manufacturing — Primary revenue source; sales increased 14% in the nine months ended March 31, 2026, driven by increased orders from one of the largest customers and new customers, partially offset by reduced orders from other existing customers. Largest customer accounted for 27% of total net sales in that period.
• Patent and trademark licensing (CarnoSyn, SR CarnoSyn, TriBsyn) — Revenue from raw material sales, royalties, and licensing; decreased 11% to $5.3 million for the nine months ended March 31, 2026, from $6.0 million a year earlier, due to lower instant-release CarnoSyn sales and royalty income, partially offset by TriBsyn sales.
• B2B private label products (SR CarnoSyn tablets, TriBsyn capsules) — Offered as business-to-business private label products, contributing to the patent estate revenue stream.

Recent performance

Net sales for the nine months ended March 31, 2026 were 13% higher than the same period in fiscal 2025. Quarterly revenue has been relatively stable: $33.9M (June 2025), $37.7M (September 2025), $34.8M (December 2025), and $35.5M (March 2026). Annual revenue declined from $178.5M in 2021 to $113.8M in 2024, then rose to $129.9M in 2025, but the company reported a net loss of $13.6M in 2025 and $7.2M in 2024. As of March 31, 2026, cash and equivalents were $9.2M, total assets $154.9M, total liabilities $91.8M, and shareholder equity $63.1M.

Strategy

Management aims to diversify its customer base and grow profitability by developing relationships with quality-oriented private-label manufacturing customers and commercializing the patent estate through sales, royalties, and licensing. It continues to invest in research and development to expand CarnoSyn brand offerings, launching new formulations like TriBsyn and CarnoSyn 4X. TriBsyn is designed for the Wellness and Healthy Aging channel, while CarnoSyn 4X targets sports nutrition with improved bioavailability. The company also announced expanded market applications for TriBsyn in beverage, dairy, and medical nutrition categories.

Risks

• Customer concentration — Revenue has historically depended on two or three large private-label customers; the largest customer represented 27% of net sales in the nine months ended March 31, 2026, down from 35% a year earlier, and order timing can cause significant revenue fluctuations.
• Economic downturn and consumer demand — A prolonged downturn could reduce consumer spending on nutritional supplements, adversely affecting customer orders and licensing revenue.
• Supply chain and geopolitical disruptions — Global instability, including the Russia-Ukraine conflict, has led to volatility in raw material availability and prices, even though those countries accounted for no direct sales in fiscal 2025 and 2024.
• Regulatory and certification risks — Manufacturing operations rely on certifications like TGA GMP certification, which is subject to renewal audits; delays or loss of certification could impact ability to export to certain markets.

Outlook

Management expects fiscal 2026 annual revenue concentration for its largest customer to be lower than in fiscal 2025, as part of diversification efforts. The company is investing in new products (TriBsyn, CarnoSyn 4X) and expanded applications to penetrate new market segments such as wellness, sports nutrition, beverage, and medical nutrition. However, management does not provide specific forward-looking financial guidance in the provided excerpts.